Page last updated: 2024-11-05

monoethylglycinexylidide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Monoethylglycinexylidide (MEG) is a synthetic compound that is structurally similar to the stimulant drug methylphenidate (Ritalin). MEG is a potent dopamine reuptake inhibitor and has been shown to have stimulant-like effects in animal studies. It is not currently approved for medical use in humans. Research into MEG is ongoing, with interest in its potential therapeutic effects for attention-deficit/hyperactivity disorder (ADHD) and other conditions.'

monoethylglycinexylidide: RN given refers to unlabeled parent cpd; metabolite of xylocaine; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

monoethylglycinexylidide : Amino acid amide formed from 2,6-dimethylaniline and N-ethylglycine components; an active metabolite of lidocaine, formed by oxidative deethylation. Used as an indicator of hepatic function. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24415
CHEMBL ID1028
CHEBI ID222828
SCHEMBL ID1232491
MeSH IDM0041268

Synonyms (56)

Synonym
CHEMBL1028
n-(2,6-dimethylphenyl)-2-(ethylamino)acetamide ,
2',6'-acetoxylidide, 2-(ethylamino)-
l-86
monoethylglycinexylidide
brn 2417108
l 86
2-ethylamino-2',6'-acetoxylidide
acetamide, n-(2,6-dimethylphenyl)-2-(ethylamino)-
2-ethylamino-2,6-acetoxylidine
n-ethylglycinexylidide
7728-40-7
smr000752507
MLS001304701
ethylglycylxylidide
MAYBRIDGE1_007633
norlidocaine
megx
HMS563C21
AKOS005082288
chebi:222828 ,
omega-(ethylamino)-2',6'-dimethylacetanilide
n-(2,6-dimethylphenyl)-n(2)-ethylglycinamide
EN300-90184
A19162
NCGC00246533-01
3-12-00-02466 (beilstein handbook reference)
d8q99hc770 ,
unii-d8q99hc770
HMS2232E09
2-(ethylamino)-2',6'-acetoxylidide
monoethylglycylxylidide
n-(n-ethylglycyl)-2,6-xylidine
FT-0636579
HMS3374F08
1G-010
lidocaine hydrochloride impurity d [ep impurity]
lidocaine impurity d [ep impurity]
2-(ethylamino)-2',6'-acetoxylidine
n-(2,6-dimethylphenyl)-2-(ethylamino)acetamide #
2-ethylamino-2',6'-acetoxylidine
.omega.-(ethylamino)-2',6'-dimethylacetanilide
DTXSID60228006
SCHEMBL1232491
Z46193731
CCG-252913
monoethylglycinexylidine, analytical standard
2-(ethylamino)-n-(2,6-dimethylphenyl)ethanamide
megx, >=95% (hplc)
n-(2,6-dimethylphenyl)-n~2~-ethylglycinamide
monoethyl glycinexylidide
l 86;norlidocaine
Q27225703
monoethyl glycinexylidine-d6 hcl
CS-0065354
HY-118167

Research Excerpts

Overview

MEGX is a hepatic metabolite of lidocaine. It is used clinically to determine graft function following hepatic transplantation.

ExcerptReferenceRelevance
"Monoethylglycinexylidide (MEGX) is a hepatic metabolite of lidocaine, used clinically to determine graft function following hepatic transplantation."( Monoethylglycinexylidide production parallels changes in hepatic blood flow and oxygen delivery in lung injury managed with positive end-expiratory pressure.
Branson, RD; Davis, K; Johnson, DJ; Purcell, PN; Schroeder, TJ, 1992
)
2.45

Effects

Monoethylglycinexylidide (MEGX) test has been used in diagnostic and prognostic assessment of chronic liver disease as a quantitative liver function test.

ExcerptReferenceRelevance
"Monoethylglycinexylidide has not previously been measured in studies on lidocaine in liposuction."( Pharmacokinetics and safety of lidocaine and monoethylglycinexylidide in liposuction: a microdialysis study.
Armstrong, VW; Brown, SA; Kenkel, JM; Lipschitz, AH; Luby, M; Oellerich, M; Rohrich, RJ; Shepherd, G; Streit, F, 2004
)
1.3
"The monoethylglycinexylidide (MEGX) test has been used in diagnostic and prognostic assessment of chronic liver disease as a quantitative liver function test."( Histologic determinants of monoethylglycinexylidide formation in patients with chronic hepatitis C.
Botta, F; Ceppa, P; Fasoli, A; Giannini, E; Risso, D; Romagnoli, P; Testa, R, 2000
)
1.08

Toxicity

ExcerptReferenceRelevance
" The peak lidocaine plus monoethylglycinexylidide concentration was within safe limits in this group of subjects."( Pharmacokinetics and safety of lidocaine and monoethylglycinexylidide in liposuction: a microdialysis study.
Armstrong, VW; Brown, SA; Kenkel, JM; Lipschitz, AH; Luby, M; Oellerich, M; Rohrich, RJ; Shepherd, G; Streit, F, 2004
)
0.89
"Data from this study demonstrate that topical anesthetic for facial rejuvenation can be enhanced with laser pretreatment while maintaining safe blood serum levels."( Topical lidocaine enhanced by laser pretreatment: a safe and effective method of analgesia for facial rejuvenation.
Kenkel, J; Oni, G; Rasko, Y, 2013
)
0.39

Pharmacokinetics

Lidocaine and its metabolites, monoethylglycinexylidide and glycinexilidide, are reduced after a partial hepatectomy. No statistically significant differences were observed in any of the pharmacokinetic parameters.

ExcerptReferenceRelevance
"3 ml/min/kg), terminal half-life (148 min), and total volume of distribution (1."( Pharmacokinetics and metabolism of lidocaine in patients with renal failure.
Atkinson, AJ; Collinsworth, KA; Harrison, DC; Perlroth, F; Strong, JM; Winkle, RA, 1975
)
0.25
"93 (control) ml/min kg], half-life [74."( Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition.
Coutts, RT; Finegan, BA; Ke, J; Koo, WW; Tam, YK, 1990
)
0.28
" 4-compartment model was introduced to analyze pharmacokinetic parameters, and which gave the most reasonable fit with actual results."( [Pharmacokinetics of lidocaine and its metabolites in dog. Comparison between normal and CCl4-induced hepatic lesion].
Yamane, J, 1989
)
0.28
" One-, two-, or three-compartment models were fitted to drug and metabolite blood concentration-time profiles and clearance, volume (Vss), and half-life values were calculated and compared by paired t-test."( The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects.
Elliott, HL; Kelman, AW; Meredith, PA; Thomson, AH; Whiting, B, 1987
)
0.27
"The pharmacokinetic parameters of lidocaine are pertinent to the determination of both appropriate loading doses and constant infusion rates that achieve a therapeutic plasma concentration while avoiding toxicity."( Pharmacokinetic principles of lidocaine dosing in relation to disease state.
Waller, ES, 1981
)
0.26
" Pharmacokinetic parameters were calculated with a noncompartimental method and compared by means of the Kruskal-Wallis test."( Pharmacokinetics of vinorelbine in patients with liver metastases.
Aita, P; Borsatti, E; Cannizzaro, R; Freschi, A; Galligioni, E; Monfardini, S; Robieux, I; Sorio, R; Vitali, V, 1996
)
0.29
" Terminal elimination half-life and apparent volume of distribution were not significantly different among groups."( Pharmacokinetics of vinorelbine in patients with liver metastases.
Aita, P; Borsatti, E; Cannizzaro, R; Freschi, A; Galligioni, E; Monfardini, S; Robieux, I; Sorio, R; Vitali, V, 1996
)
0.29
" laboratory and pharmacodynamic tests, as well as pharmacokinetic assays were performed prior to the operation as well as 10-12 days after the bile duct ligation."( Pharmacokinetics of lidocaine and its major metabolite- monoethylglycinexylidide (MEGX) in rabbits with experimental common bile duct obstruction.
Barcew-Wiszniewska, B; Droździk, M; Gawrońska-Szklarz, B; Gołdyn, U; Rózewicka, L; Skowron, J; Sulikowski, T; Wójcicki, J; Wójcicki, M,
)
0.38
" Terminal half-life (t1/2), was significantly longer in nonascitic patients than in control subjects (32 vs 22 min)."( Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.
Ferrara, SD; Frison, G; Mazzo, M; Orlando, R; Padrini, R; Palatini, P; Tedeschi, L; Zordan, R, 1996
)
0.29
" There were no differences in pharmacokinetic parameters for lidocaine between the UT and PB groups."( Effect of phenobarbital on the pharmacokinetics of lidocaine, monoethylglycinexylidide and 3-hydroxylidocaine in the rat: correlation with P450 isoform levels.
Fujimori, M; Funae, Y; Imaoka, S; Nakamoto, T; Oda, Y, 1997
)
0.54
"The aim of the study was to evaluate the effect of experimental diabetes on pharmacokinetic parameters of lidocaine and its metabolite monoethyl-glycylxylidide (MEGX) after a single intravenous administration in rats."( Effect of experimental diabetes on pharmacokinetic parameters of lidocaine and MEGX in rats.
Gawrońska-Szklarz, B; Musiał, DH; Paprota, B; Pawlik, A,
)
0.13
" No statistically significant differences were observed in any of the pharmacokinetic parameters; peak concentrations, concentration peak times or elimination half-lives of lidocaine or monoethylglycinexylidide."( Effect of itraconazole on the pharmacokinetics of inhaled lidocaine.
Isohanni, MH; Neuvonen, PJ; Olkkola, KT, 2004
)
0.51
"Anesthesia with isoflurane significantly decreased the volume of the central compartment, clearance, and elimination half-life of lidocaine and significantly increased the extrapolated plasma drug concentration at time 0, compared with values for awake cats."( Pharmacokinetics of lidocaine and its active metabolite, monoethylglycinexylidide, after intravenous administration of lidocaine to awake and isoflurane-anesthetized cats.
Ilkiw, JE; Pypendop, BH; Stanley, SD; Thomasy, SM, 2005
)
0.57
" When pharmacokinetic variables are used to determine loading and infusion doses in awake or anesthetized cats, they should be measured in cats that are awake or anesthetized, respectively."( Pharmacokinetics of lidocaine and its active metabolite, monoethylglycinexylidide, after intravenous administration of lidocaine to awake and isoflurane-anesthetized cats.
Ilkiw, JE; Pypendop, BH; Stanley, SD; Thomasy, SM, 2005
)
0.57
"Ciprofloxacin increased the mean peak concentration and area under plasma concentration-time curve of lidocaine by 12% (range [-6] to+46%; P<0."( Effect of ciprofloxin on the pharmacokinetics of intravenous lidocaine.
Ahonen, J; Isohanni, MH; Neuvonen, PJ; Olkkola, KT, 2005
)
0.33
" During the fluvoxamine phase the area under the plasma concentration-time curve (AUC) and peak concentration (Cmax) of oral lidocaine were 305% (P<0."( Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
Isohanni, MH; Neuvonen, PJ; Olkkola, KT, 2006
)
0.33
" Pharmacokinetic parameters were compared with data from a previous study performed in healthy volunteers."( Pharmacokinetics of tilidine and naloxone in patients with severe hepatic impairment.
Brennscheidt, U; Brunnmüller, U; Proppe, D; Seiler, KU; Thomann, P, 2007
)
0.34
"Peridural blockade with lidocaine, bupivacaine, and fentanyl is an anesthetic procedure extensively used in obstetrics, justifying the pharmacokinetic study of these drugs during labor."( Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus.
Cavalli, Rde C; da Cunha, SP; Duarte, G; Duarte, Lde B; Lanchote, VL; Marques, MP; Moisés, EC, 2008
)
0.35
" Maternal blood samples were collected at predetermined times for the analysis of lidocaine and MEGX by chromatography and pharmacokinetic analysis."( Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus.
Cavalli, Rde C; da Cunha, SP; Duarte, G; Duarte, Lde B; Lanchote, VL; Marques, MP; Moisés, EC, 2008
)
0.35
" Pharmacokinetic parameters were obtained by non-compartmental methods and ratio of AUC of MEGX divided by AUC of lidocaine was determined for each dog."( Pharmacokinetics of lidocaine and its metabolite as a hepatic function marker in dogs.
Carrasco-Portugal, MC; Flores-Murrieta, FJ; González-Zamora, JF; Jiménez-Bravo, MA; Pérez-Guillé, BE; Soriano-Rosales, RE; Toledo-López, A; Villegas-Alvarez, F, 2011
)
0.37
" The hypothesis was that the elimination clearance of lidocaine and its metabolites, monoethylglycinexylidide and glycinexylidide, is reduced after a partial hepatectomy, as reflected by observed plasma concentrations that are higher and have a longer half-life than expected based on pharmacokinetic modeling (estimated for normal liver function)."( Lidocaine Intraoperative Infusion Pharmacokinetics during Partial Hepatectomy for Living Liver Donation.
Christians, U; Crouch, CE; Fernandez-Bustamante, A; Hendrickse, A; Henthorn, TK; Kaizer, AM; Schniedewind, B; Wilkey, BJ, 2023
)
1.13
" Pharmacokinetic modeling revealed that the only significant covariate in the model was the fraction of liver remaining after isolation of the donor graft."( Lidocaine Intraoperative Infusion Pharmacokinetics during Partial Hepatectomy for Living Liver Donation.
Christians, U; Crouch, CE; Fernandez-Bustamante, A; Hendrickse, A; Henthorn, TK; Kaizer, AM; Schniedewind, B; Wilkey, BJ, 2023
)
0.91
" Lidocaine and metabolite concentrations were determined by liquid chromatography- mass spectrometry and pharmacokinetic (non-compartmental and compartmental) analysis was performed."( Pharmacokinetics and metabolism of lidocaine HCl 2% with epinephrine in horses following a palmar digital nerve block.
Arthur, RM; Blea, J; Katzman, S; Knych, HK; McKemie, DS, 2023
)
0.91
"Compared to previous reports, the terminal half-life and subsequent detection time observed following administration of lidocaine in combination with epinephrine is prolonged."( Pharmacokinetics and metabolism of lidocaine HCl 2% with epinephrine in horses following a palmar digital nerve block.
Arthur, RM; Blea, J; Katzman, S; Knych, HK; McKemie, DS, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
"PABA is well absorbed by the gastrointestinal tract and acetylated and conjugated in the liver to glycine before being excreted."( Preliminary assessment of glycine conjugation of para-aminobenzoic acid as a quantitative test of liver function.
Barr, SB; Duffy, LF; Kerzner, B; Seeff, L; Soldin, SJ, 1995
)
0.29
"Lignocaine is metabolized by cytochrome P450 3A4 enzyme (CYP3A4), and has a moderate to high extraction ratio resulting in oral bioavailability of 30%."( Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine.
Isohanni, MH; Neuvonen, PJ; Olkkola, KT, 1999
)
0.3
" The effect of this 'nasal first-pass' should be weighed carefully while considering the fate and the bioavailability of drugs delivered via the intranasal route."( Characterization of lidocaine metabolism by rat nasal microsomes: implications for nasal drug delivery.
Desai, PB; Deshpande, VS; Genter, MB; Jung, C,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" A computer-aided simulation generated from using the mean kinetic data in a 50-kg woman predicted that plasma lidocaine concentration would reach the postulated toxic range (approximately equal to 6 microgram/ml) after the fourth supplementary dose under a similar dosing scheme as performed in this study."( Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia.
Echizen, H; Inoue, R; Ishizaki, T; Kushida, K; Suganuma, T; Tomono, Y, 1985
)
0.27
" The reasons and mechanism for this difference between subjects on multiple dosing remains unclear."( Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man.
Aarons, LJ; Bending, MR; Bennett, PN; Rowland, M; Steiner, JA, 1982
)
0.26
" Lidoncaine, 5 x 10(-4) M, and MEGX, 2 x 10(-3) M, shifted the dose-response curve of NE to the right, whereas GX, 5 x 10(-4) M, shifted the curve to the left."( Modifications by lidocaine and its N-dealkylated metabolites of the response of the isolated rabbit aorta to transmural electrical stimulation.
Fukuda, S; Takeshita, H; Toda, N, 1980
)
0.26
"We have investigated the importance of cytochrome P-450IIIA enzyme activity in influencing dosage of the immunosuppressive drugs FK 506 and cyclosporine after liver transplantation."( Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients.
Cakaloglu, Y; Devlin, J; Tredger, JM; Williams, R, 1994
)
0.29
" Nonetheless, GHB plasma concentrations fell to either undetectable or negligible levels by the end of the usual dosing intervals (6-8 h)."( Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.
Ferrara, SD; Frison, G; Mazzo, M; Orlando, R; Padrini, R; Palatini, P; Tedeschi, L; Zordan, R, 1996
)
0.29
"Etoposide dosage in patients with liver dysfunction remains controversial."( Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita, P; Boiocchi, M; Cannizzaro, R; Colussi, AM; Corona, G; Robieux, I; Sorio, R; Toffoli, G; Tumolo, S, 1999
)
0.3
" In conclusion, dosage modification is necessary in hypercholesterolemia."( [The effect of hyperlipidemia on metabolism, distribution and secretion of lidocaine in patients with primary hyperlipidemia].
Rózański, J, 2000
)
0.31
" However, it is not known what plasma levels are obtained when the same dosage is used in children."( Pharmacokinetics of lidocaine delivered from a transmucosal patch in children.
Leopold, A; Moursi, AM; Weaver, JS; Wilson, S, 2002
)
0.31
" The clinical implication of this study is that no lidocaine dosage adjustments are necessary if it is used to prepare the airway prior to endoscopic procedures or intubation in patients using itraconazole or other inhibitors of CYP3A4."( Effect of itraconazole on the pharmacokinetics of inhaled lidocaine.
Isohanni, MH; Neuvonen, PJ; Olkkola, KT, 2004
)
0.32
" Plasma concentrations of free (unbound) and total valdecoxib and its active hydroxylated metabolite (SC-66905) were measured following single and multiple dosing (day 1 and day 8)."( The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor.
Britto, MR; Mainka, MB; Parivar, K; Sarapa, N, 2005
)
0.33
" The adjustment of valdecoxib dose or dosing regimen does not appear mandatory in subjects with mild or moderate hepatic impairment, although caution is necessary during treatment of these patients with valdecoxib."( The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor.
Britto, MR; Mainka, MB; Parivar, K; Sarapa, N, 2005
)
0.33
" Decreased hepatic metabolism after resection raises concerns about safe lidocaine dosing in this patient population."( Lidocaine Intraoperative Infusion Pharmacokinetics during Partial Hepatectomy for Living Liver Donation.
Christians, U; Crouch, CE; Fernandez-Bustamante, A; Hendrickse, A; Henthorn, TK; Kaizer, AM; Schniedewind, B; Wilkey, BJ, 2023
)
0.91
" Clearance of lidocaine is decreased proportionally to the remaining liver mass, which should guide lidocaine infusion administration or dosing adjustments for patients undergoing liver resection surgery."( Lidocaine Intraoperative Infusion Pharmacokinetics during Partial Hepatectomy for Living Liver Donation.
Christians, U; Crouch, CE; Fernandez-Bustamante, A; Hendrickse, A; Henthorn, TK; Kaizer, AM; Schniedewind, B; Wilkey, BJ, 2023
)
0.91
" Clearance of lidocaine is decreased proportionally to the remaining liver mass, which should guide lidocaine infusion administration or dosing adjustments for patients undergoing liver resection surgery."( Lidocaine Intraoperative Infusion Pharmacokinetics during Partial Hepatectomy for Living Liver Donation.
Christians, U; Crouch, CE; Fernandez-Bustamante, A; Hendrickse, A; Henthorn, TK; Kaizer, AM; Schniedewind, B; Wilkey, BJ, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
amino acid amideAn amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Lidocaine (Antiarrhythmic) Action Pathway4922
Lidocaine (Local Anaesthetic) Action Pathway3325
Lidocaine (Local Anaesthetic) Metabolism Pathway416
Lidocaine Pathway, Pharmacokinetics75
Lidocaine metabolism08

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency2.81840.044717.8581100.0000AID485294
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency1.00000.707936.904389.1251AID504333
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency0.18360.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1148541Drug level in po dosed human urine treated with lidocaine1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
N-Hydroxyamide metabolites of lidocaine. Synthesis, characterization, quantitation, and mutagenic potential.
AID1148534Genotoxicity in Salmonella typhimurium TA-1538 after 2 days by Ames test relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
N-Hydroxyamide metabolites of lidocaine. Synthesis, characterization, quantitation, and mutagenic potential.
AID1210886Drug metabolism in human liver microsomes assessed as retention time treated with 25 to 8000 uM lidocaine incubated for 5 mins prior to NADPH addition measured after 25 mins by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
AID190117Neurologic toxicity from rotarod test in rats, perorally2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds.
AID1148548Plasma concentration in ventricular arrthymia patient at 1.4 mg/min, iv administered for 36 hrs measured after 30 hrs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
N-Hydroxyamide metabolites of lidocaine. Synthesis, characterization, quantitation, and mutagenic potential.
AID121992Neurologic toxicity from rotarod test in mice2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds.
AID1148547Drug level in ventricular arrthymia patient urine treated with lidocaine at 1.4 mg/min, iv administered for 36 hrs measured after 30 hrs measured after 30 hrs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
N-Hydroxyamide metabolites of lidocaine. Synthesis, characterization, quantitation, and mutagenic potential.
AID1148535Genotoxicity in Salmonella typhimurium TA-1538 after 2 days by Ames test in presence of C57BL/6J mouse liver S9 fraction relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
N-Hydroxyamide metabolites of lidocaine. Synthesis, characterization, quantitation, and mutagenic potential.
AID177049Compound was evaluated for anticonvulsant activity by maximal electroshock seizure test, perorally in rats2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds.
AID114630Compound was evaluated for anticonvulsant activity by maximal electroshock seizure test, intraperitoneally in mice2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (323)

TimeframeStudies, This Drug (%)All Drugs %
pre-199050 (15.48)18.7374
1990's166 (51.39)18.2507
2000's80 (24.77)29.6817
2010's22 (6.81)24.3611
2020's5 (1.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.51 (24.57)
Research Supply Index6.00 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials58 (16.76%)5.53%
Reviews10 (2.89%)6.00%
Case Studies8 (2.31%)4.05%
Observational0 (0.00%)0.25%
Other270 (78.03%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]